NCT00540579 - CC-4047 With Gemcitabine for Untreated Advanced Carcinoma of the Pancreas | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

December 31, 2008

Study Completion Date

January 31, 2011

Conditions

Pancreatic Cancer

Interventions

DRUG

Pomalidomide

Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21

DRUG

Gemcitabine

1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle

Trial Locations (2)

37023

Tennessee Oncology, PLLC, Nashville

80045

University of Colorado Cancer Center, Aurora